Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial

•Canakinumab is a monoclonal antibody to the proinflammatory cytokine Interleukin-1β.•People with schizophrenia and elevated peripheral inflammation enrolled in a trial.•Canakinumab reduced peripheral c-reactive protein and positive symptom severity.•C-reactive protein level change was related to ch...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Brain, behavior, and immunity behavior, and immunity, 2024-01, Vol.115, p.191-200
Hauptverfasser:	Weickert, Thomas W., Jacomb, Isabella, Lenroot, Rhoshel, Lappin, Julia, Weinberg, Danielle, Brooks, William S., Brown, David, Pellen, Daniel, Kindler, Jochen, Mohan, Adith, Wakefield, Denis, Lloyd, Andrew R., Stanton, Clive, O'Donnell, Maryanne, Liu, Dennis, Galletly, Cherrie, Shannon Weickert, Cynthia
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-inflammatory drug Antibodies, Monoclonal - therapeutic use Australia Blood biomarker C-Reactive Protein C-Reactive Protein - analysis Canakinumab Chronic Disease Double-Blind Method Humans Inflammation Inflammation - drug therapy Interleukin-1β Interleukin-6 Positive Symptoms Randomized double-blind placebo-control trial Schizophrenia Schizophrenia - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!